See more : Technical Communications Corporation (TCCO) Income Statement Analysis – Financial Results
Complete financial analysis of Pangenomic Health Inc. (NARA.CN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Pangenomic Health Inc., a leading company in the Medical – Healthcare Information Services industry within the Healthcare sector.
- COL Digital Publishing Group Co., Ltd. (300364.SZ) Income Statement Analysis – Financial Results
- Svenska Nyttobostäder AB (publ) (NYTTO-PREF.ST) Income Statement Analysis – Financial Results
- Adani Enterprises Limited (ADANIENT.BO) Income Statement Analysis – Financial Results
- Zahav Inc. (ZAHA) Income Statement Analysis – Financial Results
- EnergyPathways plc (EPP.L) Income Statement Analysis – Financial Results
Pangenomic Health Inc. (NARA.CN)
Industry: Medical - Healthcare Information Services
Sector: Healthcare
Website: https://www.pangenomic.com
About Pangenomic Health Inc.
Pangenomic Health Inc., a precision health company, develops a self-care digital platform to deliver personalized and evidence-based information about natural treatments to support mental health. It develops the Nara App, a mobile app that provides consumers with a knowledge base tailored to an individual's unique user profile; and the PlantGx Platform, a digital therapeutics clinic platform that provides health practitioners with access to user health data enabled from the Nara App by the patient and to receive patient referrals. The company was formerly known as Zetta Capital Corp. and changed its name to PanGenomic Health Inc. in December 2021. Pangenomic Health Inc. was incorporated in 2015 and is headquartered in Vancouver, Canada.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 681.43K | 11.11K | 2.13K | 0.00 | 0.00 |
| Gross Profit | -681.43K | -11.11K | -2.13K | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 253.78K | 534.11K | 129.67K | 0.00 | 0.00 |
| General & Administrative | 1.32M | 2.60M | 655.23K | 134.86K | 72.00 |
| Selling & Marketing | 280.61K | 495.69K | 81.63K | 136.81K | 0.00 |
| SG&A | 1.78M | 3.10M | 736.86K | 136.95K | 72.00 |
| Other Expenses | 0.00 | 11.11K | 2.13K | 0.00 | 0.00 |
| Operating Expenses | 2.03M | 3.64M | 868.66K | 136.95K | 3.44K |
| Cost & Expenses | 2.71M | 3.64M | 868.66K | 136.95K | 3.44K |
| Interest Income | 2.38K | 2.45K | 15.84K | 278.00 | 0.00 |
| Interest Expense | 44.04K | 1.31K | 2.47K | 3.32K | 0.00 |
| Depreciation & Amortization | 12.40K | 11.11K | 2.13K | 134.86K | 72.00 |
| EBITDA | -2.71M | -3.57M | -847.50K | -1.81K | -3.37K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -2.71M | -3.64M | -852.81K | -136.95K | -72.00 |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -261.14K | -8.43M | -1.80M | -3.04K | -3.37K |
| Income Before Tax | -2.97M | -11.99M | -2.65M | -139.99K | -3.44K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 8.35M | 2.47K | -134.86 | -3.37 |
| Net Income | -2.97M | -20.35M | -2.65M | -139.99K | -3.44K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.30 | -2.19 | -1.34 | -0.24 | -0.01 |
| EPS Diluted | -0.30 | -2.19 | -1.34 | -0.24 | -0.01 |
| Weighted Avg Shares Out | 9.99M | 5.48M | 1.98M | 586.00K | 586.00K |
| Weighted Avg Shares Out (Dil) | 9.99M | 5.48M | 1.98M | 586.94K | 586.94K |
Source: https://incomestatements.info
Category: Stock Reports